Acknowledgments
Atusaye Ngwira
DISEASE, FRANKLIN
This study received financial support from the European & Developing Countries Clinical Trials Partnership 2 (EDCTP2) programme supported by the EU (grant number TRIA-2015-1076-IMPROVE to the Liverpool School of Tropical Medicine [LSTM], Liverpool, UK) and the UK Joint Global-Health-Trials (JGHT) Scheme funded by the Department of Health and Social Care, Foreign, Commonwealth and Development Office, Medical Research Council, and Wellcome (grant reference MR/P006914/1 to LSTM), and from the Bill & Melinda Gates Foundation (INV-002781). We thank Montserrat Blázquez-Domingo from EDCTP2 for her support in managing the grant on behalf of EDCTP2 and JGHT. Eurartesim was provided free of charge by AlfaSigma. We thank all the study participants and all the research assistants who did the study. We are grateful to the members of the Trial Steering Committee (Laurence Slutsker, Matthew Cairns, Miriam Laufer, Grant Dorsey, and Per Ashorn) and the Data Safety and Monitoring Board (Andy Stergachis, Kathleen Wannemuehler, Ib Christian Bygbjerg, William Ngasala, and Christian Funck-Brentano) for their expertise and guidance in conducting the trial and independent review of the safety data, study protocol, and statistical analysis plan. We thank Franklin Mosha for hosting the study at the Kilimanjaro Clinical Research Institute and Kilimanjaro Christian Medical University College, Moshi, Tanzania. We also thank Tracy Seddon, Helen Wong, and Katie Davies in Liverpool, UK; Benta Kamire and Sheila Nyarinda in Kisumu, Kenya; Christopher Masaka in Dar es Salaam and Amina Farah in Moshi, Tanzania; and Zainab Longwe, Jones Chakholoma, and Palinji Mungoni in Blantyre, Malawi for their managerial and administrative support. We thank Kelly Byrne from the Global Health Trials Unit at LSTM for trial management and pharmacovigilance support. We also thank the Directors of Ahero sub-County Hospital, Rabuor sub-County Hospital, Homa Bay County Referral Hospitals, and Akala Health Centre in Siaya for accommodating the study in Kenya; the Medical Officers in charge of Korogwe District Hospital (Magunga), Handeni District Hospital, and Bombo Referral Regional hospitals for accommodating the study in Tanzania; and the Directors and staff of Blantyre, Chikwawa, Mangochi, and Zomba District Health Offices for accommodating the study in Malawi. We thank Jane Mallewa in Malawi and Gerald Yonga in Kenya for providing support with the cardiac monitoring component, and Nickline Kuya Ashitiba and Evelyne Delylah Ondieki for trial coordination in Kenya. We thank Atusaye Ngwira in Malawi; Henry Aura and Micah June in Kenya; and Mohamed Mapondela, Joyce Mbwana, and Edwin Nyale in Tanzania for technical support and internal monitoring; John Chabuka and John Lino for external monitoring oversight; and Bernard Owino and Martina Oneko for safety monitoring. We also thank Tao Chen for supporting the Data Safety and Monitoring Board as the independent statistician with access to the study code and Tony Sang, the lead pharmacist, for support with the preparations of study drugs. This study is published with the permission of the Director of KEMRI. The LSTM was the sponsor. The findings and conclusions in this publication are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention or the US Department of Health and Human Services.